Neuromod Devices Limited (“Neuromod”), an Irish medical technology company specializing in non-invasive neuromodulation technologies, announced that Professor Richard S. Tyler has agreed to join Neuromod’s Clinical Advisory Board. A clinical expert in tinnitus and audiology, Tyler is a pioneer in the advancement of tinnitus research and treatment, founding the annual International Conference on Management of Tinnitus and Hyperacusis more than 26 years ago. In addition to his roles as professor in the Department of Otolaryngology, Head & Neck Surgery and in the Department of Speech Pathology and Audiology at the University of Iowa, Tyler continues to see and treat a large number of US tinnitus patients.
Professor Richard Tyler, PhD
Tyler’s appointment to the Clinical Advisory Board follows a number of other appointments by the company this year. In June, Christopher M. Smith, a leader in the hearing and medical device industries, agreed to join the Board of Directors and in January, Professor Hubert Lim, a scientist and thought leader in auditory neuroscience, was appointed as Chief Scientific Officer.
Commenting on the appointment, Dr Ross O’Neill, CEO of Neuromod, said, “We’re delighted to welcome Professor Rich Tyler to Neuromod’s Clinical Advisory Board. Professor Tyler is a world-renowned audiologist who has advanced our understanding of tinnitus and pioneered research into the development of treatments for tinnitus throughout his illustrious career. As a practicing audiologist who continues to see and help a large number of tinnitus patients, Professor Tyler’s insight and guidance will be invaluable as we prepare for the commercial rollout of our groundbreaking, home-use tinnitus treatment device.”
“There are estimates of up to 30% of the population suffering from tinnitus and no one seems to want to help them,” said Tyler. “Many of these patients cannot sleep at night and take medications for anxiety and depression. I am excited to join Neuromod’s Clinical Advisory Board. Neuromod is working with leading tinnitus scientists and are taking an evidence-based approach to develop treatments for this large unmet clinical need. They have conducted some of the largest and most rigorous clinical trials to date in tinnitus. I am glad to play a part in helping them develop viable treatment options for the millions of patients living with this debilitating condition.”
Neuromod Team, L-R: Emma Meade, clinical coordinator; Rich Tyler; Caroline Hamilton, clinical audiologist; Dr Hubert Lim CSO, Dr Ross O’Neill CEO.
Hearing Review published an interview with Tyler in 2017 in recognition of the 25th anniversary of the International Conference on Management of the Tinnitus and Hyperacusis Patient, in which he discussed the tinnitus treatment methods developed by his department at the University of Iowa.
Source: Neuromod
Images: Neuromod
